Can commercial choices materially improve the program's trajectory?
01
From development to durable adoptionBiotech commercialization
Complex therapeutics need commercial thinking long before launch. Hekla brings hands-on strategy and organization-building experience to rare disease, gene therapy, and novel-modality companies.
01 Direct answer
Where Hekla fits
Hekla works with therapeutic companies navigating the path from development through global commercial launch, with an emphasis on translating clinical promise into a credible, patient-centered commercial plan.
Opportunity fit
What we look for
- 01Rare disease, gene therapy, and novel-modality platforms
- 02Commercial organization design and launch readiness
- 03Global market access and payer strategy
- 04Partnership, licensing, and portfolio strategy
Operating contribution
What we can bring
- 01Commercial strategy built around the real development path
- 02Launch sequencing, capability maps, and decision milestones
- 03Cross-functional operating cadence and organizational design
- 04Market-access framing grounded in stakeholder needs
02 Decision lens
Questions that shape our first view.
Is the team ready to make evidence, access, and launch decisions early?
Can Hekla's operating experience fill a defined capability gap?